Company: STAA
Filing Date: 2025-09-02
Form Type: DEFA14A
Source: 0001193125-25-194146
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-09-02
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☒ | Soliciting Material under §240.14a-12 |

STAAR SURGICAL COMPANY (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11                                                           |

STAAR Surgical Company (the “Company”) issued the following press release on September 2, 2025:

STAAR Surgical Reiterates Compelling, Premium Cash Value Provided by Alcon Merger

LAKE FOREST, CA, September2, 2025—- STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO
family of Implantable Collamer Lenses (EVO ICL) for vision correction, issued the following statement:

“The merger with Alcon provides STAAR stockholders with compelling, premium cash value, including a 51% premium to the closing price of
STAAR common stock on August 4, 2025 (the day prior to the agreement being announced), and a 59% premium to STAAR’s 90-day Volume Weighted Average Price (VWAP) as of that date.

We believe the $28 per share cash value provided by the Alcon agreement exceeds what STAAR could achieve on a standalone basis in the
foreseeable future, particularly, given STAAR’s lower growth rate and the resulting impact on its valuation, and the substantial competitive and macro challenges in the markets STAAR serves. STAAR is heavily exposed to China, which faces
significant economic uncertainty and where sales